ArticleIntensive care medicine2015
Association of prior antiplatelet agents with mortality in sepsis patients: a nationwide population-based cohort study.
Article in Intensive care medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 5 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Impact of antiplatelet therapy on outcomes of sepsis: A systematic review and meta-analysis.PloS one · 2025Pooled it
- The preventive effect of antiplatelet therapy in acute respiratory distress syndrome: a meta-analysis.Critical care (London, England) · 2018Pooled it
- Quantifying the Effects of Prior Acetyl-Salicylic Acid on Sepsis-Related Deaths: An Individual Patient Data Meta-Analysis Using Propensity Matching.Critical care medicine · 2017Pooled it
- Effect of Antiplatelet Therapy on Acute Respiratory Distress Syndrome and Mortality in Critically Ill Patients: A Meta-Analysis.PloS one · 2016Pooled it
- Effect of antiplatelet therapy on mortality and acute lung injury in critically ill patients: A systematic review and meta-analysis.Annals of cardiac anaesthesiaPooled it
- Cytokine and lipid metabolome effects of low-dose acetylsalicylic acid in critically ill patients with systemic inflammation: a pilot, feasibility, multicentre, randomised, placebo-controlled trial.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2020Trial
- Treatment With Acetylsalicylic Acid Reverses Endotoxin Tolerance in Humans In Vivo: A Randomized Placebo-Controlled Study.Critical care medicine · 2019Trial
- Trial
- Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.Arteriosclerosis, thrombosis, and vascular biology · 2015Trial
- Aspirin is associated with improved outcomes in sepsis patients with atrial fibrillation: an analysis of the MIMIC-IV and eICU-CRD databases.Frontiers in cardiovascular medicine · 2026Article
- A cecal slurry mouse model of polymicrobial abdominal sepsis to evaluate the effects of antiplatelet agents.Research and practice in thrombosis and haemostasis · 2026Article
- Aspirin improves short and long term survival outcomes of patients with sepsis associated encephalopathy.Scientific reports · 2025Article
- Aspirin is associated with a reduction in mortality rate for patients with sepsis-induced coagulopathy: a retrospective cohort study.Frontiers in pharmacology · 2025Article
- Aspirin is associated with improved 30-day mortality in patients with sepsis-associated liver injury: a retrospective cohort study based on MIMIC IV database.Frontiers in pharmacology · 2025Article
- Construction and Validation of a Predictive Model for Mortality Risk in Patients withInfection and drug resistance · 2024Article
- A Predictive Model for Disseminated Intravascular Coagulopathy in Sepsis: An Observational Study.International journal of general medicine · 2024Article
- Aspirin reduces the mortality risk of sepsis-associated acute kidney injury: an observational study using the MIMIC IV database.Frontiers in pharmacology · 2023Article
- Article
- Intracellular communication and immunothrombosis in sepsis.Journal of thrombosis and haemostasis : JTH · 2022Review
- The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia.Trends in cardiovascular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntiplatelet agents are widely used for cardiovascular disea ses, but their pleiotropic effects in sepsis are controversial.
objectiveTo investigate the association between antiplatelet agents and the survival benefit for sepsis patients.
designA nationwide population-based cohort and nested case-control study.
settingTaiwan National Health Insurance database.
participantsAll patients (age ≥18 years) who were hospitalized for sepsis between January 2000 and December 2010. MEASUREMENTS: Conditional logistic regression was used to adjust for confounding. Adjusted odd ratios (ORs) were used to compare the mortality rate due to sepsis in antiplatelet drug users and nonusers.
resultsOf 683,421 included patients, 229,792 (33.6 %) patients died during hospitalization for sepsis, and the rest (64.4 %) survived to discharge. Use of antiplatelet agents before admission was associated with a lower risk of mortality in sepsis patients (aOR 0.82, 95 % confidence interval [CI] 0.81-0.83, P < 0.001). By using another case-control study design, the beneficial effect was more significant in current users (aOR 0.78, 95 % CI 0.76-0.79) than in recent users (aOR 0.88, 95 % CI 0.85-0.91), but was not significant in past users (aOR 1.00, 95 % CI 0.98-1.02). LIMITATIONS: Observational study.
conclusionsPrior use of antiplatelet agents was associated with a survival benefit in sepsis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.